

Name	<b>ANNA TAVRIDOU</b>
Rank/Title	Assistant Professor (2/2009- )
Topic/Specialty	Pharmacology
Department	Laboratory of Pharmacology
Office	5 <sup>th</sup> Building, 1 <sup>st</sup> Floor, Dragana, Alexandroupolis
Phone	25510 30530
Fax	25510 30530
Email	atavrid@med.duth.gr
Research Interests	<ul style="list-style-type: none"> <li>➤ Pathophysiology of atherosclerosis: in vitro studies (culturing of monocytes, hepatocytes, endothelial cells) and in vivo (animal models). Assessment of biomarkers for identifying subjects with atherosclerotic disease or involved in drug response</li> <li>➤ Pathophysiology of osteoarthritis: study of cytokines in human biological samples and effect of drugs</li> <li>➤ Mechanism of action of hypolipidemic, antihypertensive, antiatherosclerotic molecules</li> <li>➤ Study of genetic polymorphisms involved in: a) the pathogenesis of cardiovascular and other disease, b) response to drugs targeting the cardiovascular and other systems, c) drug metabolism</li> </ul>
Teaching	<ul style="list-style-type: none"> <li>❑ “Pharmacology I” &amp; “Pharmacology II”, Medical School, Democritus University of Thrace</li> <li>❑ Postgraduate course “Clinical Pharmacology-Therapeutics”, Democritus University of Thrace &amp; University of Crete</li> <li>❑ Supervising a) dissertations of undergraduate students at the Department of Molecular Biology and Genetics, b) postgraduate students at the Medical School of Democritus University of Thrace</li> </ul>
Link to personal webpage	
<b>Detailed Biographical Information</b>	
Education	<ul style="list-style-type: none"> <li>▪ BSc in Pharmacy, Aristotle University of Thessaloniki, Greece (1985-1989)</li> <li>▪ MSc in Clinical Biochemistry, The Medical School, University of Newcastle, UK (1994-1995)</li> <li>▪ PhD in Medicine, The Medical School, University of Newcastle, UK (1995-1999)</li> </ul>
Scientific Experience	<ul style="list-style-type: none"> <li>➤ Lecturer in Pharmacology, Medical School, Democritus University of Thrace (9/2004-2/2009)</li> <li>➤ Head of Laboratory of Pharmacology, ELPEN Pharmaceuticals Co. Inc (2000-2004)</li> <li>➤ Postdoctoral researcher funded by the Medical Research Council: Human Diabetes &amp; Metabolism Research Centre, The Medical School, University of Newcastle, UK (1999-2000)</li> <li>➤ Research Associate funded by the British Heart Foundation, Dept. of Clinical</li> </ul>

	Biochemistry, The Medical School, University of Newcastle, UK (1995-1998)
Published work	<ul style="list-style-type: none"> <li>○ PhD thesis: Lipoprotein(a) in population-based samples of South Asian and European adults in Newcastle upon Tyne</li> <li>○ MSc dissertation: Analysis of antioxidant vitamins and their assessment in a population-based sample</li> <li>○ 34 scientific articles in international peer-reviewed journals</li> <li>○ 44 abstracts in Proceedings of international conferences and 43 abstracts in Proceedings of Greek conferences</li> <li>○ Teaching material in Pharmacology</li> <li>○ 2 book chapters (pages 75-79 &amp; 167-171) in Atherosclerosis-Cardiometabolic risk factors, A.N. Efthimiadis. 2008</li> <li>○ 1 book chapter (pages 383-439) in Molecular pharmacology topics in cardiovascular system, V.A. Kokkas, K.L. Papadopoulos. 2011</li> </ul>
Publications	<p><i>Citations: 430 (April 2011 according to ISI Web of Knowledge-Web of Science).</i></p> <p><i>Impact factor (IF)</i></p> <ul style="list-style-type: none"> <li>➤ Mean IF: 3.163</li> <li>➤ Sum IF: 107.56</li> </ul> <p><i>H-index: 10</i></p> <ol style="list-style-type: none"> <li>1. Tavidou A, Ragia G, and Manolopoulos VG (2011) Emerging targets for the treatment of dyslipidemia. <i>Curr Med Chem</i> 18:909-922</li> <li>2. Tavidou A, Efthimiadis A, Efthimiadis I, and Manolopoulos VG (2010) Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia. <i>Heart Vessels</i> 25:288-293</li> <li>3. Ragia G, Nikolaidis E, Tavidou A, Arvanitidis KI, Kanoni S, Dedoussis GV, Bougioukas G, and Manolopoulos VG (2010) Endothelial nitric oxide synthase gene polymorphisms - 786T &gt; C and 894G &gt; T in coronary artery bypass graft surgery patients. <i>Hum Genomics</i> 4:375-383</li> <li>4. Ragia G, Nikolaidis E, Tavidou A, Arvanitidis KI, Kanoni S, Dedoussis GV, Bougioukas G, and Manolopoulos VG (2010) Renin-angiotensin-aldosterone system gene polymorphisms in coronary artery bypass graft surgery patients. <i>J Renin Angiotensin Aldosterone Syst</i> 11:136-145</li> <li>5. Manolopoulos VG, Ragia G, and Tavidou A (2010) Pharmacogenetics of coumarinic oral anticoagulants. <i>Pharmacogenomics</i> 11:493-496</li> <li>6. Iordanidou M, Tavidou A, Petridis I, Kyroglou S, Kaklamanis L, Christakidis D, and Manolopoulos VG (2010) Association of polymorphisms of the serotonergic system with smoking initiation in Caucasians. <i>Drug Alcohol Depend</i> 108:70-76</li> <li>7. Iordanidou M, Tavidou A, Petridis I, Arvanitidis KI, Christakidis D, Vargemezis V, and Manolopoulos VG (2010) The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes. <i>Clin Chim Acta</i> 411:167-171</li> <li>8. Tavidou A, and Manolopoulos VG (2009) Inhibitors of 5-lipoxygenase activating protein: WO 2008/030369. <i>Expert Opin Ther Pat</i> 19:1473-1476</li> <li>9. Tavidou A, and Manolopoulos VG (2009) EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors. <i>Curr Pharm Des</i> 15:3167-3178</li> <li>10. Tavidou A, Arvanitidis KI, Tiptiri-Kourpeti A, Petridis I, Ragia G, Kyroglou S, Christakidis D, and Manolopoulos VG (2009) Thr54 allele of fatty-acid binding protein 2 gene is associated with obesity but not type 2 diabetes mellitus in a Caucasian population. <i>Diabetes Res Clin Pract</i> 84:132-137</li> <li>11. Stakos DA, Tavidou A, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Manolopoulos VG, and Boudoulas H (2009) Oxidised low-density lipoprotein and arterial function in beta-thalassemia major. <i>Eur J Haematol</i> 82:477-483</li> </ol>

12. Ragia G, Petridis I, Tavidou A, Christakidis D, and Manolopoulos VG (2009) Presence of CYP2C9\*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. *Pharmacogenomics* 10:1781-1787
13. Ragia G, Arvanitidis KI, Tavidou A, and Manolopoulos VG (2009) Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19\*17 discovery: the case of Greece. *Pharmacogenomics* 10:43-49
14. Manolopoulos VG, and Tavidou A (2009) Drugs targeting atherosclerosis: current and emerging approaches. *Curr Pharm Des* 15:3091-3093
15. Tavidou A, and Manolopoulos VG (2008) Novel molecules targeting dyslipidemia and atherosclerosis. *Curr Med Chem* 15:792-802
16. Tavidou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A, and Manolopoulos VG (2008) Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit. *J Cardiovasc Pharmacol* 51:573-580
17. Iordanidou M, Tavidou A, Vasiliadis MV, Arvanitidis KI, Petridis J, Christakidis D, Vargemezis V, Bougioukas G, and Manolopoulos VG (2008) The -759C/T polymorphism of the 5-HT<sub>2C</sub> receptor is associated with type 2 diabetes in male and female Caucasians. *Pharmacogenet Genomics* 18:153-159
18. Tavidou A, Megaritis G, Kourounakis AP, Charalambous A, and Manolopoulos VG (2007) EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells. *Endothelium* 14:239-243
19. Tavidou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A, and Manolopoulos VG (2007) EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit. *J Pharmacol Exp Ther* 323:794-804
20. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavidou A, and Manolopoulos VG (2007) Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. *Fundam Clin Pharmacol* 21:419-426
21. Tavidou A, Kaklamanis L, Megaritis G, Kourounakis AP, Papalois A, Roukounas D, Rekka EA, Kourounakis PN, Charalambous A, and Manolopoulos VG (2006) Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. *Eur J Pharmacol* 535:34-42
22. Tavidou A, Efthimiadis A, Efthimiadis I, and Paschalidou H (2006) Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease. *Eur J Clin Pharmacol* 62:485-489
23. Vryonidou A, Papatheodorou A, Tavidou A, Terzi T, Loi V, Vatalas IA, Batakis N, Phenekos C, and Dionyssiou-Asteriou A (2005) Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 90:2740-2746
24. Tavidou A, and Manolopoulos VG (2005) Atorvastatin and simvastatin decrease the uptake of acetylated low-density lipoprotein by human monocytes. *Pharmacology* 73:102-105
25. Tavidou A, and Manolopoulos VG (2004) Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo. *Eur J Pharmacol* 505:213-221
26. Tavidou A, Unwin N, Bhopal R, and Laker MF (2003) Predictors of lipoprotein(a) levels in a European and South Asian population in the Newcastle Heart Project. *Eur J Clin Invest* 33:686-692
27. Tavidou A, and Agius L (2003) Phosphorylase regulates the association of glycogen synthase with a proteoglycan substrate in hepatocytes. *FEBS Lett* 551:87-91
28. Tavidou A, and Laker MF (1999) Field inversion gel electrophoresis for apolipoprotein(a) genotyping. *Anal Biochem* 272:282-285
29. Bhopal R, Unwin N, White M, Yallop J, Walker L, Alberti KG, Harland J, Patel S, Ahmad N, Turner C, Watson B, Kaur D, Kulkarni A, Laker M, and

	<p>Tavridou A (1999) Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. <i>Bmj</i> 319:215-220</p> <p>30. Tavridou A, Unwin NC, Laker MF, White M, and Alberti KG (1997) Serum concentrations of vitamins A and E in impaired glucose tolerance. <i>Clin Chim Acta</i> 266:129-140</p> <p>31. Tavridou A, Avranas A, and Arzoglou P (1992) A mathematical approach to lipolysis based on the interrelationship of physicochemical and biochemical data. <i>Biochem Biophys Res Commun</i> 186:746-752</p> <p>32. Lessinger JM, Tavridou A, Arzoglou P, and Ferard G (1992) Interest of using a purified, stable and commutable preparation of human pancreatic lipase in indirect assays. <i>Analytical Letters</i> 25:1453-1468</p> <p>33. Arzoglou PL, Tavridou A, Lessinger JM, Tzimas G, and Ferard G (1992) Spectrophotometric determination of lipase activity in the presence of increased triolein concentration. <i>Ann Biol Clin (Paris)</i> 50:155-160</p> <p>34. Arzoglou PL, Tavridou A, and Balaska C (1989) Rapid turbidimetric determination of lipase activity in biological fluids. <i>Analytical Letters</i> 22:1459-1470</p>
R&D Projects	<ol style="list-style-type: none"> <li>1. Genetic prognostic markers of cardiovascular disease</li> <li>2. Genetic risk factors of atherosclerosis in type 2 diabetic patients</li> <li>3. Risk factors of vascular calcification in diabetic nephropathy</li> <li>4. Study of adipokines in patients with osteoarthritis</li> <li>5. Genetic risk factors of asthma and genetic factors involved in drug response</li> <li>6. A pharmacogenomic approach to coumarin anticoagulant therapy</li> </ol>
Clinical Work	2005- Therapeutic drug monitoring: Laboratory of Clinical Pharmacology, University General Hospital of Alexandroupolis
Miscellaneous	<ul style="list-style-type: none"> <li>➤ Membership in Professional Bodies: <ul style="list-style-type: none"> <li>- Northern Greece Atherosclerosis Society (founding member, Treasurer, 2007-2010, 2010-2013)</li> <li>- European Atherosclerosis Society</li> <li>- Greek Society of Pharmacology</li> </ul> </li> <li>➤ Member of Organizing Committees of conferences and seminars</li> <li>➤ Reviewer of research proposals submitted at the General Secretariat for Research and Technology</li> <li>➤ Reviewer of articles submitted for publication in international journals</li> <li>➤ Invited speaker/chairman in national and international conferences</li> </ul>